A Reversal for Chiasma Inc (CHMA) Is Not Near. The Stock Rises Again

September 17, 2017 - By test

The stock of Chiasma Inc (NASDAQ:CHMA) is a huge mover today! The stock increased 4.35% or $0.1 on September 15, reaching $2.4. About 101,535 shares traded. Chiasma Inc (NASDAQ:CHMA) has declined 48.76% since September 17, 2016 and is downtrending. It has underperformed by 65.46% the S&P500.
The move comes after 9 months positive chart setup for the $58.46M company. It was reported on Sep, 17 by Barchart.com. We have $2.62 PT which if reached, will make NASDAQ:CHMA worth $5.26 million more.

Chiasma Inc (NASDAQ:CHMA) Ratings Coverage

Among 3 analysts covering Chiasma (NASDAQ:CHMA), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. Chiasma had 6 analyst reports since August 10, 2015 according to SRatingsIntel. As per Tuesday, January 17, the company rating was downgraded by Barclays Capital. Barclays Capital initiated it with “Overweight” rating and $40 target in Monday, August 10 report. Cowen & Co initiated the stock with “Outperform” rating in Monday, August 10 report. The rating was downgraded by William Blair on Monday, April 18 to “Market Perform”. Barclays Capital downgraded Chiasma Inc (NASDAQ:CHMA) rating on Monday, April 25. Barclays Capital has “Equal-Weight” rating and $5.50 target. The firm has “Outperform” rating given on Monday, August 10 by William Blair.

More important recent Chiasma Inc (NASDAQ:CHMA) news were published by: Streetinsider.com which released: “Chiasma, Inc. (CHMA) Announces Agreement with FDA Under SPA for New Phase 3 …” on August 10, 2017, also Globenewswire.com published article titled: “Chiasma Names Mark J. Fitzpatrick Chief Executive Officer”, Marketwatch.com published: “2.50” on June 18, 2015. More interesting news about Chiasma Inc (NASDAQ:CHMA) was released by: Globenewswire.com and their article: “Chiasma Recognizes Acromegaly Awareness Day with New Resources for Patients …” with publication date: November 01, 2016.

Chiasma, Inc. is a biopharmaceutical company. The company has market cap of $58.46 million. The Firm is engaged in developing and commercializing oral forms of therapies that are available only by injection. It currently has negative earnings. Using its Transient Permeability Enhancer technology platform, the Company is developing oral therapies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.